
|Videos|October 21, 2022
EP. 10A: Impact of Trilaciclib on Chemotherapy-Induced Myelosuppression in Patients with ES-SCLC
Author(s)Mark A. Socinski, MD
Dr Mark Socinski reviews the challenges faced when treating chemotherapy induced myelosuppression and discusses the impact of trilaciclib on CIM and how that will impact clinical practice.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Advanced Renal Cell Carcinoma: Summarizing a Practical First-Line Treatment Algorithm
2
On-Body Injector Technology Streamlines Subcutaneous Myeloma Therapy
3
Allostatic Load: The Role of Chronic Stress in Predicting Early-Onset Cancer Risk
4
Exploring Psilocybin-Assisted Therapy for Cancer Patients' Trauma
5










































